Ranbaxy Disappointed By U.S. FDA’s Warning Letters And “Import Alert”
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's largest drug maker Ranbaxy expressed its disappointment over U.S. FDA's move to issue warning letters and import alerts against drug products manufactured at its sites in Dewas in Madhya Pradesh and Paonta Sahib in Himachal Pradesh
You may also be interested in...
Ranbaxy Reports Higher Than Expected Loss; India Earnings Roundup
MUMBAI - India's largest drug maker Ranbaxy, now controlled by Japan's Daiichi Sankyo, shocked financial analysts with a much higher than expected loss of 679.8 crore rupees ($142 million) during its fourth quarter as compared to a net profit of 187.80 crore ($39 million) in the corresponding quarter of 2007
Ranbaxy Reports Higher Than Expected Loss; India Earnings Roundup
MUMBAI - India's largest drug maker Ranbaxy, now controlled by Japan's Daiichi Sankyo, shocked financial analysts with a much higher than expected loss of 679.8 crore rupees ($142 million) during its fourth quarter as compared to a net profit of 187.80 crore ($39 million) in the corresponding quarter of 2007
Ranbaxy May Face Third-Party Oversight Of Ganciclovir Manufacturing
Ranbaxy may be subject to third-party supervision of its manufacturing of the antiviral ganciclovir, in return for gaining an exception for the product from U.S. FDA's Import Alert